## Abstract p53, a cellular‐encoded protein, is synthesized at elevated levels in a wide range of tumor cells. Ab‐MuLV‐transformed cells expressing both the viral‐encoded p120 oncogene and the cellular‐encoded p53 display a lethal tumor phenotype in syngeneic mice. L12 is an exceptional Ab‐MuLV‐tra
Expression of the MuLV-tumor-associated antigen is restricted to MuLV-transformed cells
✍ Scribed by David C. Flyer; Brian Sucheski
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- French
- Weight
- 630 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Immunization of mice with Moloney murine leukemia virus (MoMuLV) induces the generation of a population of CTL which recognizes a non-viral, tumor-associated antigen FAA) expressed on MuLV-induced tumors. To determine whether this TAA could be used as a pre-leukemic or leukemic cell marker, CTL clones directed against Moloney viral and TAA antigen were used to analyze viral and TAA antigen expression on chronically infected and leukemic lymphoid cells obtained from mice inoculated neonatally with MoMuLV. Although both sets of cells could be recognized and lysed by viral antigen specific CTL, they are not recognized by TAA-specific CTL. Only after transformed cell lines were established from leukemic spleen cells could susceptibility to TAA-specific CTL be observed. Thus, the appearance of the MoMuLV-TAA was restricted to MoMuLV-transformed cells.
📜 SIMILAR VOLUMES
Mucin-associated sialylated Lewis antigens are implicated in tumor cell metastasis and are used in several tests for pancreatic cancer. Despite their clinical importance, little is known about the structures of the oligosaccharides of pancreatic cancer mucins or about the regulation of their synthes
## Abstract A tumor rejection antigen (TSTA) has been solubilized by DOC ^1^ from purified plasma membranes of an R‐MuLV‐induced leukemia, RBL‐5. Gel filtration chromatography resulted in the separation of high molecular weight fractions containing TSTA from lower molecular weight fractions contain
## Abstract To improve tumor targeting in a subset of patients, where tumor cells do not express the well‐known tumor antigens widely used in immunotherapy, we have developed a novel biotechnological tool. It is useful for tumors of various origins for the identification of tumor‐associated protein
## Abstract The fetal antigens expressed in a variety of tumors have previously been shown to be different from tumor‐specific antigens. The present study on the expression of fetal antigens in various SV40‐transformed cells showed that more than one fetal antigen may be found in these cell lines,